IDH is a very important prognostic, diagnostic and therapeutic biomarker for glioma, and triggered the integrated genomic-histological characterization of brain tumours proposed in the 2016 World Health Organization (WHO) classification system1. This evidence concerns the gene IDH1 and central nervous system cancer.